Skip to main content
. 2021 Mar 22;7(1):00480-2020. doi: 10.1183/23120541.00480-2020

FIGURE 3.

FIGURE 3

Incremental cost-effectiveness of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus budesonide (BUD)/formoterol (FOR): (a) life year (LY) plane; (b) quality-adjusted life year (QALY) plane; (c) QALY cost-effectiveness acceptability curves (intent to treat (ITT) population; probabilistic analysis).